Medinet announced that it would discontinue in-house development in Japan of a regenerative medicine product that had received manufacturing and marketing approval in India. The focus will be on reviewing its future development policy.
Medinet announced a policy to discontinue in-house development in Japan of a regenerative medicine product that received manufacturing and marketing approval in India. The announcement was made on 30 October 2026 and disclosed as timely disclosure.
The announcement clearly indicates that development activities in the Japanese market will not continue, suggesting a divergence between the approval obtained in India and the development plan in Japan. Further disclosures and the extent of its future accountability are expected to attract attention.
In connection with this, Medinet is expected to reconsider its strategy for in-house development of regenerative medicine products in Japan, but the article does not specify a future timetable or alternative policy. The content of the timely disclosure will continue to be monitored.